89bio, Inc.
ETNBDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Pegozafermin
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
BIO89-100
NASH - Nonalcoholic Steatohepatitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Pegozafermin | Phase 3 | Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis | - | - |
BIO89-100 | Phase 2 | NASH - Nonalcoholic Steatohepatitis | - | - |
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
1 drug in this indication
NASH - Nonalcoholic Steatohepatitis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in 89bio, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in 89bio, Inc.'s (ETNB) pipeline across Phase 3, Phase 2. Its lead program is Pegozafermin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is 89bio, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for 89bio, Inc. (ETNB) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ETNB biotech catalysts?→
Add ETNB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow 89bio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.